sotalol has been researched along with Wolff-Parkinson-White Syndrome in 19 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Wolff-Parkinson-White Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We determined the effects of combined sotalol (160 mg/day) and flecainide (200 mg/day) in 15 patients with the Wolff-Parkinson-White syndrome." | 7.68 | Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome. ( Gössinger, HD; Mösslacher, H; Siostrzonek, P, 1990) |
| "The electrophysiologic effects of sotalol were studied in 11 patients with Wolff-Parkinson-White syndrome and 9 patients with AV nodal reentrant tachycardia." | 7.67 | [Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia]. ( Kuhl, AJ; Lüderitz, B; Manz, M, 1985) |
| "Sotalol has Class II and III antiarrhythmic effects." | 5.28 | Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol. ( Madrid, AH; Maŕin Huerta, EM; Mestre, JL; Moro, C; Novo, L, 1992) |
| " Serum sotalol concentration, maximum exercise heart rate, and electrophysiologic study data were obtained at control, at the beta-adrenoceptor-blocking dosage (407 +/- 149 mg/day, 1." | 5.27 | Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. ( Duff, HJ; Mitchell, LB; Wyse, DG, 1987) |
| "Sotalol was administered intravenously (n = 16) in a dose of 1." | 5.27 | [Electrophysiologic effect of sotalol in supraventricular tachycardias]. ( Borggrefe, M; Breithardt, G, 1985) |
| "We determined the effects of combined sotalol (160 mg/day) and flecainide (200 mg/day) in 15 patients with the Wolff-Parkinson-White syndrome." | 3.68 | Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome. ( Gössinger, HD; Mösslacher, H; Siostrzonek, P, 1990) |
| "6 mg/kg sotalol, a beta-blocking agent with additional class III properties, were studied by means of electrophysiologic techniques in 14 patients, seven with the Wolff-Parkinson-White syndrome and seven with concealed atrioventricular (AV) accessory pathways." | 3.67 | Effects of intravenous sotalol in patients with atrioventricular accessory pathways. ( Atallah, G; Dellinger, A; Kirkorian, G; Lavaud, P; Mathieu, MP; Touboul, P, 1987) |
| "The effects of oral Sotalol were assessed by electrophysiological investigations in 6 patients with ventricular preexcitation (Wolff-Parkinson-White syndrome) and a short anterograde refractory period (less than or equal to 280 ms) of the accessory pathway." | 3.67 | [Effects of oral sotalol on the conduction of accessory atrioventricular pathways]. ( Blanc, JJ; Boschat, J; Ollivier, JP; Penther, P, 1985) |
| "The electrophysiologic effects of sotalol were studied in 11 patients with Wolff-Parkinson-White syndrome and 9 patients with AV nodal reentrant tachycardia." | 3.67 | [Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia]. ( Kuhl, AJ; Lüderitz, B; Manz, M, 1985) |
| " Little justification for the use of agents or dosing in children is available." | 2.40 | Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry. ( Kuhn, RJ; Luedtke, SA; McCaffrey, FM, 1997) |
| "Sotalol treatment was stopped and an infusion with lidocaine was started." | 1.30 | Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate. ( Bergmann, P; Kallfelz, HC; Paul, T; Sasse, M, 1998) |
| "Sotalol has Class II and III antiarrhythmic effects." | 1.28 | Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol. ( Madrid, AH; Maŕin Huerta, EM; Mestre, JL; Moro, C; Novo, L, 1992) |
| "Association of long QT with arrhythmia does not, therefore, invalidate the principle that homogeneously prolonged APD should be anti-arrhythmic." | 1.27 | Delayed ventricular repolarization as an anti-arrhythmic principle. ( Vaughan Williams, EM, 1985) |
| " Serum sotalol concentration, maximum exercise heart rate, and electrophysiologic study data were obtained at control, at the beta-adrenoceptor-blocking dosage (407 +/- 149 mg/day, 1." | 1.27 | Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. ( Duff, HJ; Mitchell, LB; Wyse, DG, 1987) |
| "Sotalol was administered intravenously (n = 16) in a dose of 1." | 1.27 | [Electrophysiologic effect of sotalol in supraventricular tachycardias]. ( Borggrefe, M; Breithardt, G, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (47.37) | 18.7374 |
| 1990's | 9 (47.37) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nathan, AW | 1 |
| Hellestrand, KJ | 1 |
| Bexton, RS | 1 |
| Ward, DE | 1 |
| Spurrell, RA | 1 |
| Camm, AJ | 1 |
| Bennett, DH | 1 |
| Sasse, M | 2 |
| Paul, T | 2 |
| Bergmann, P | 2 |
| Kallfelz, HC | 2 |
| Daubert, C | 1 |
| Mabo, P | 1 |
| Gras, D | 1 |
| Leclercq, C | 1 |
| Luedtke, SA | 1 |
| Kuhn, RJ | 1 |
| McCaffrey, FM | 1 |
| Yu, WC | 1 |
| Chen, SA | 1 |
| Tai, CT | 1 |
| Wen, ZC | 1 |
| Feng, AN | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
| Price, JF | 1 |
| Kertesz, NJ | 1 |
| Snyder, CS | 1 |
| Friedman, RA | 1 |
| Fenrich, AL | 1 |
| Madrid, AH | 1 |
| Moro, C | 1 |
| Maŕin Huerta, EM | 1 |
| Novo, L | 1 |
| Mestre, JL | 1 |
| Inama, G | 1 |
| Furlanello, F | 1 |
| Vergara, G | 1 |
| Guarnerio, M | 1 |
| Braito, G | 1 |
| Nassivera, E | 1 |
| Gössinger, HD | 1 |
| Siostrzonek, P | 1 |
| Mösslacher, H | 1 |
| Millar, RN | 1 |
| Vaughan Williams, EM | 1 |
| Mitchell, LB | 1 |
| Wyse, DG | 1 |
| Duff, HJ | 1 |
| Kunze, KP | 1 |
| Schlüter, M | 1 |
| Kuck, KH | 1 |
| Touboul, P | 1 |
| Atallah, G | 1 |
| Kirkorian, G | 1 |
| Lavaud, P | 1 |
| Mathieu, MP | 1 |
| Dellinger, A | 1 |
| Blanc, JJ | 1 |
| Boschat, J | 1 |
| Ollivier, JP | 1 |
| Penther, P | 1 |
| Manz, M | 1 |
| Kuhl, AJ | 1 |
| Lüderitz, B | 1 |
| Borggrefe, M | 1 |
| Breithardt, G | 1 |
2 reviews available for sotalol and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Humans; | 1993 |
Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Ch | 1997 |
2 trials available for sotalol and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
[Sotalol in the Wolff-Parkinson-White syndrome: an electrophysiological and clinical study].
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Fema | 1992 |
Efficacy of sotalol in controlling reentrant supraventricular tachycardias.
Topics: Adolescent; Adult; Aged; Electrocardiography; Female; Humans; Male; Middle Aged; Sotalol; Tachycardi | 1990 |
15 other studies available for sotalol and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Electrophysiological effects of sotalol--just another beta blocker?
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Child; Electrocardiography; Female; Heart; Heart Cond | 1982 |
Acute prolongation of myocardial refractoriness by sotalol.
Topics: Action Potentials; Administration, Oral; Adult; Heart; Heart Conduction System; Humans; Infusions, P | 1982 |
[Sotalol-induced torsade de pointes tachycardia in a 15-month-old infant].
Topics: Anti-Arrhythmia Agents; Aspartic Acid; Electrocardiography; Female; Humans; Infant; Sotalol; Torsade | 1995 |
Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.
Topics: Anti-Arrhythmia Agents; Aspartic Acid; Electrocardiography; Female; Humans; Infant; Sotalol; Torsade | 1998 |
Effects of procainamide and dl-sotalol on the changes of atrial electrophysiology induced by high current stimulation.
Topics: Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Function; Atrial Premature Complex | 1998 |
Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Com | 2002 |
Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Conductio | 1992 |
Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome.
Topics: Adult; Drug Combinations; Female; Flecainide; Follow-Up Studies; Humans; Male; Refractory Period, El | 1990 |
Delayed ventricular repolarization as an anti-arrhythmic principle.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bund | 1985 |
Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.
Topics: Adult; Atrioventricular Node; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow- | 1987 |
Sotalol in patients with Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Adult; Cardiac Pacing, Artificial; Electrocardiography; Exercise Test; Female; | 1987 |
Effects of intravenous sotalol in patients with atrioventricular accessory pathways.
Topics: Adolescent; Adult; Aged; Female; Heart Conduction System; Humans; Injections, Intravenous; Male; Mid | 1987 |
[Effects of oral sotalol on the conduction of accessory atrioventricular pathways].
Topics: Administration, Oral; Adult; Atrial Fibrillation; Electrocardiography; Female; Heart Conduction Syst | 1985 |
[Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia].
Topics: Adult; Atrioventricular Node; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Conduct | 1985 |
[Electrophysiologic effect of sotalol in supraventricular tachycardias].
Topics: Adolescent; Adult; Atrioventricular Node; Cardiac Pacing, Artificial; Electrocardiography; Female; H | 1985 |